In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CIMA Labs Inc.

Division of Teva Pharmaceutical Industries Ltd.

Latest From CIMA Labs Inc.

Opioids Need Comparative Deterrence Studies, FDA Panel Says

Review of oral, nasal and intravenous abuse-deterrence claims for Teva's long-acting hydrocodone Vantrela ER highlights the lack of head-to-head studies against approved abuse-deterrent formulations and spurs debate on relevant comparators.

BioPharmaceutical United States

Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence

Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.

BioPharmaceutical United States

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Cephalon: Can Spec Pharma do R&D?

Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • James C Hawley, CFO
    Douglas E Moran, Dir., Bus. Dev.
  • Contact Info
  • CIMA Labs Inc.
    Phone: (952) 947-8700
    10000 Valley View Rd.
    Eden Prairie, MN 55344